Efficacy and Safety of Riociguat in Incipient Pulmonary Vascular Disease as an Indicator for Early PAH

Clinical trial NCT05339087 · TERMINATED

Trial details

NCT number: NCT05339087
Sponsor: Heidelberg University
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Pulmonary Vascular Disorder Primary Pulmonary Hypertension Systemic Sclerosis Other Systemic Involvement of Connective Tissue

Start date: 2022-10-24
Primary completion: 2025-07-31
Enrollment: 35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.